Dr. Gutierrez on the Safety Profile of Pembrolizumab-Based Combos in NSCLC

In Partnership With:

Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).

In the phase II KEYNOTE-495/KeylmPaCT trial (NCT03516981), patients with treatment-naïve, advanced NSCLC who do not harbor EGFR and BRAF mutations or ALK and ROS1 gene rearrangements will be grouped into 4 categories depending on their T cell-inflamed gene expression profile and tumor mutational burden. Each group will be randomized to receive pembrolizumab plus either MK-4280, lenvatinib (Lenvima), or the CTLA-4 inhibitor MK-1308.

The recommended phase II dose of MK-1308 and pembrolizumab has been established, says Gutierrez. A slight increase in immune-related adverse events was reported with the combination; however, this was expected. According to phase I data, MK-4280 was well tolerated. Regarding the combination of pembrolizumab and lenvatinib, investigators have yet to see an increase in toxicity beyond what is expected with lenvatinib alone, concludes Gutierrez.

Related Videos
View All
Related Content